Literature DB >> 15541482

Rituximab in primary conjunctiva lymphoma.

Pier Luigi Zinzani1, Lapo Alinari, Vittorio Stefoni, Antonio Loffredo, Patrizia Pichierri, Ennio Polito.   

Abstract

Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15541482     DOI： 10.1016/j.leukres.2004.05.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  5 in total

1.  Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.

Authors:  Masayuki Takahira; Hirokazu Okumura; Hiroshi Minato; Norimasa Urushisaki; Mayumi Sakurai; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2007-04-06       Impact factor: 2.447

Review 2.  A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma.

Authors:  Maurilio Ponzoni; Silvia Govi; Giada Licata; Silvia Mappa; Antonio Giordano Resti; Letterio S Politi; Lorenzo Spagnuolo; Eliana Di Cairano; Claudio Doglioni; Andrés J M Ferreri
Journal:  Oncologist       Date:  2013-06-28

3.  Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.

Authors:  Ombretta Annibali; Francesca Chiodi; Chiara Sarlo; Magdalena Cortes; Francesco M Quaranta-Leoni; Carlo Quattrocchi; Antonella Bianchi; Stefano Bonini; Giuseppe Avvisati
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 4.  Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy.

Authors:  Salvatore Perrone; Gianna Maria D'Elia; Giorgia Annechini; Alessandro Pulsoni
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-01-01       Impact factor: 2.576

5.  Rituximab in the treatment of non-Hodgkin's lymphoma.

Authors:  Beate Hauptrock; Georg Hess
Journal:  Biologics       Date:  2008-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.